Harrow, Inc. (NASDAQ:HROW) Stake Lowered by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC decreased its stake in Harrow, Inc. (NASDAQ:HROW - Free Report) by 4.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 296,172 shares of the company's stock after selling 14,339 shares during the period. Rice Hall James & Associates LLC owned approximately 0.83% of Harrow worth $7,878,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Westside Investment Management Inc. boosted its position in shares of Harrow by 6.3% in the first quarter. Westside Investment Management Inc. now owns 173,856 shares of the company's stock worth $4,625,000 after buying an additional 10,315 shares during the period. Woodmont Investment Counsel LLC boosted its position in shares of Harrow by 27.4% in the first quarter. Woodmont Investment Counsel LLC now owns 103,693 shares of the company's stock worth $2,758,000 after buying an additional 22,293 shares during the period. Rhumbline Advisers boosted its position in shares of Harrow by 7.2% in the first quarter. Rhumbline Advisers now owns 42,975 shares of the company's stock worth $1,143,000 after buying an additional 2,879 shares during the period. GAMMA Investing LLC boosted its position in shares of Harrow by 2,401.2% in the first quarter. GAMMA Investing LLC now owns 6,278 shares of the company's stock worth $1,670,000 after buying an additional 6,027 shares during the period. Finally, GF Fund Management CO. LTD. purchased a new stake in shares of Harrow in the fourth quarter worth about $25,000. Hedge funds and other institutional investors own 72.76% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently commented on HROW. BTIG Research began coverage on Harrow in a research note on Thursday, June 12th. They issued a "buy" rating and a $62.00 price target on the stock. William Blair began coverage on Harrow in a research note on Tuesday, June 10th. They issued an "outperform" rating on the stock. HC Wainwright boosted their price target on Harrow from $57.00 to $60.00 and gave the stock a "buy" rating in a research note on Monday, May 12th. Cantor Fitzgerald began coverage on Harrow in a research note on Friday, July 11th. They issued an "overweight" rating and a $76.00 price target on the stock. Finally, B. Riley cut their price target on Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, Harrow has an average rating of "Buy" and a consensus target price of $63.83.

Harrow Stock Up 4.6%

NASDAQ HROW traded up $1.59 on Thursday, hitting $36.14. 563,874 shares of the stock traded hands, compared to its average volume of 499,709. The stock has a 50-day moving average of $29.90 and a 200 day moving average of $28.86. Harrow, Inc. has a twelve month low of $20.85 and a twelve month high of $59.23. The company has a market capitalization of $1.33 billion, a P/E ratio of -64.53 and a beta of 0.41. The company has a current ratio of 0.91, a quick ratio of 0.85 and a debt-to-equity ratio of 2.01.

Harrow (NASDAQ:HROW - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.40). The company had revenue of $47.83 million for the quarter, compared to the consensus estimate of $57.00 million. Harrow had a negative net margin of 10.19% and a negative return on equity of 25.01%. As a group, analysts expect that Harrow, Inc. will post -0.53 earnings per share for the current fiscal year.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.